Drugs Monitor, Page 6

(12 Apr 2021) Methylprednisolone- demonstrated better results compared to dexamethasone in hypoxic patients

April 29, 2021

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial https://doi.org/10.1186/s12879-021-06045-3 IRCT20200204046369N1- In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020,… Continue reading "(12 Apr 2021) Methylprednisolone- demonstrated better results compared to dexamethasone in hypoxic patients"

(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS

April 29, 2021

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1905794 CTRI/2020/05/024959- Patients were randomized (2:1) to Arm-A (best supportive care [BSC]+Itolizumab) and Arm-B (BSC).… Continue reading "(10 Apr 2021) Itolizumab- was found to be safe and effective immunomodulatory therapy for the treatment of CRS"

(09 Apr 2021) Tocilizumab- reduced ICU admissions and mechanical ventilation in early stages

April 29, 2021

Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection https://doi.org/10.37201/req/037.2021 A retrospective study of 171 patients with SARS-CoV-2 infection that did not qualify as requiring transfer to ICU during the first 24h after admission to… Continue reading "(09 Apr 2021) Tocilizumab- reduced ICU admissions and mechanical ventilation in early stages"

(06 Apr 2021) Adenosine- inhaled adenosine led to improvement of the prognosis indices, NLR and PLR

April 29, 2021

Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients https://doi.org/10.3389/fimmu.2021.613070 The use of inhaled adenosine in COVID19 patients has allowed reduction of length of stay, on average 6 days. This result is strengthened by the decrease in SARS-CoV-2… Continue reading "(06 Apr 2021) Adenosine- inhaled adenosine led to improvement of the prognosis indices, NLR and PLR"

(06 Apr 2021) Tocilizumab- early administration was associated with decreased mortality in critically ill patients

April 29, 2021

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2 https://doi.org/10.1097/CCE.0000000000000395 Eighty-one patients received tocilizumab, and 37 were untreated and served as a control group. Measurements and Main Results: The main… Continue reading "(06 Apr 2021) Tocilizumab- early administration was associated with decreased mortality in critically ill patients"

(06 Apr 2021) Hydroxychloroquine- in this underpowered trial patients did not experience better clinical outcomes

April 29, 2021

Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial https://doi.org/10.1016/j.cmi.2021.03.005 The trial was stopped after 250 patients were included due to a slowdown of the pandemic in France. The intention-to-treat population comprised 123 and 124 patients in the placebo and… Continue reading "(06 Apr 2021) Hydroxychloroquine- in this underpowered trial patients did not experience better clinical outcomes"

(06 Apr 2021) Chloroquine- shows preventive effect if administered before the infection is established

April 29, 2021

Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial https://doi.org/10.4103/ijmr.IJMR_3665_20 Nasal CQN was associated with local irritation in seven and non-compliance in one of 30 patients. Clinical recovery was noted as similar with 100 per cent… Continue reading "(06 Apr 2021) Chloroquine- shows preventive effect if administered before the infection is established"

(06 Apr 2021) Remdesivir- did not produce improvement in clinical outcomes in moderate to severe COVID-19 cases

April 29, 2021

Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study https://doi.org/10.4103/ija.IJA_149_21 Participants more than 40-years old and with moderate to severe COVID-19 but not on mechanical ventilation were randomly assigned into two groups-remdesivir group… Continue reading "(06 Apr 2021) Remdesivir- did not produce improvement in clinical outcomes in moderate to severe COVID-19 cases"

(02 Apr 2021) Corticosteroids- not associated with a difference in hospital mortality for patients with OSCI 3-5

April 29, 2021

Effect of corticosteroids on mortality in hospitalized COVID-19 patients not receiving invasive mechanical ventilation https://doi.org/10.1002/cpt.2245 Aim of this observational, single centre, prospective study was to assess the association between corticosteroids and hospital mortality in COVID-19 patients who did not receive… Continue reading "(02 Apr 2021) Corticosteroids- not associated with a difference in hospital mortality for patients with OSCI 3-5"

(02 Apr 2021) Favipiravir- safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients

April 29, 2021

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial https://doi.org/10.1038/s41598-021-85227-0 NCT04349241- t was randomized-controlled open-label interventional phase 3 clinical trial. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir… Continue reading "(02 Apr 2021) Favipiravir- safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients"